https://priyalifescience.com/article/korea-biosimilar-approvals-keytruda-pembrolizumab-2026 Priya Life Science en 2026-11-05T13:00:02+00:00 Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda https://priyalifescience.com/article/arraypatch-3-2-million-seed-glp-1-microneedle-patch-cork-2026 Priya Life Science en 2026-11-05T12:47:47+00:00 ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch https://priyalifescience.com/article/sun-pharma-assam-eye-care-production-halt-2026 Priya Life Science en 2026-11-05T08:30:01+00:00 Sun Pharma Told to Halt Eye-Care Production at Assam Plant https://priyalifescience.com/article/menopause-diet-cancer-free-guide-second-edition-2026 Priya Life Science en 2026-11-04T17:00:01+00:00 Free Menopause After Cancer Diet Guide Gets Second Edition https://priyalifescience.com/article/northern-ireland-endometriosis-services-investment-2026 Priya Life Science en 2026-11-04T15:00:02+00:00 Northern Ireland Invests £1.95m in Endometriosis Services https://priyalifescience.com/article/amgen-fda-warning-letter-vectibix-promotional-video-2026 Priya Life Science en 2026-11-04T13:00:01+00:00 FDA Warning Letter Cites Amgen Vectibix Promotional Video https://priyalifescience.com/article/fda-inovio-voceryq-dna-immunotherapy-rrp-approval-2026 Priya Life Science en 2026-11-04T11:00:01+00:00 FDA Approves Inovio's Voceryq DNA Immunotherapy for RRP https://priyalifescience.com/article/fda-mounjaro-cardiovascular-risk-label-surpass-cvot-2026 Priya Life Science en 2026-11-04T08:30:02+00:00 FDA Heart-Risk Label for Mounjaro: What It Means for Ireland https://priyalifescience.com/article/fresenius-wuxi-biologics-biosimilars-agreement-37-candidates-2026 Priya Life Science en 2026-11-03T17:00:02+00:00 Fresenius and WuXi Biologics Sign 37-Biosimilar Deal https://priyalifescience.com/article/hpra-medsafetyweek-2026-report-side-effects Priya Life Science en 2026-11-03T15:00:03+00:00 MedSafetyWeek 2026: HPRA asks Ireland to report side effects